Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial.

Abstract

BACKGROUND:

Varenicline and bupropion are efficacious, prescription-only pharmacotherapies for smoking cessation; however, their real-world impact is limited by prescriber knowledge, affordability, and accessibility.

OBJECTIVE:

The primary objective of the MATCH (Medication Aids for Tobacco Cessation Health) study was to evaluate the real-world, long-term effectiveness of mailed bupropion and varenicline in a sample of interested smokers with the utilization of Web-based recruitment and follow-up. In addition, the study aims to investigate the genotypic and phenotypic predictors of cessation.

METHODS:

This is a two-group, parallel block, randomized (1:1) open-label clinical trial. This study will be conducted online with the baseline enrollment through the study's website and follow-up by emails. In addition, medication prescriptions will be filled by the study contract pharmacy and couriered to participants. Individuals who smoke ≥10 cigarettes per day and intend to quit within the next 30 days will be recruited through Public Health Units and Tobacco Control Area Networks throughout Ontario by word-of-mouth and the internet. Eligible participants will receive an email with a prescription for 12-week assigned medication and a letter to take to their physician. The recruitment and randomization will continue until 500 participants per arm have received medication. All participants will receive weekly motivational emails during the treatment phase. The primary outcome measure is the smoking status after 6 months, biochemically confirmed by mailed-in salivary cotinine. Follow-ups will be conducted through emails after 4, 8, 12, 26, and 52 weeks of starting the treatment to assess the smoking prevalence and continuous smoking abstinence. In addition, mailed-in saliva samples will be used for genetic and nicotine metabolism analyses. Furthermore, personality characteristics will be assessed using the Big Five Aspect Scales.

RESULTS:

The project was funded in 2014 and enrollment was completed in January 2017. Data analysis is currently underway.

CONCLUSIONS:

To the best of our knowledge, this is the first randomized controlled trial to mass distribute prescription medications for smoking cessation. We expect this method to be logistically feasible and cost effective with quit outcomes that are comparable to published clinical trials.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02146911; https://clinicaltrials.gov/ct2/show/NCT02146911 (Archived by WebCite at http://www.webcitation.org/72CZ6AvXZ).

REGISTERED REPORT IDENTIFIER:

RR1-10.2196/10826.

• Authors: Laurie Zawertailo, Tara Mansoursadeghi-Gilan, Helena Zhang, Sarwar Hussain, Bernard Le Foll, Peter Selby
• Journal: JMIR research protocols (JMIR Res Protoc) Vol. 7 Issue 10 Pg. e10826 (Oct 18 2018) ISSN: 1929-0748 [Print] Canada
• PMID: 30341043 (Publication Type: Journal Article)
• Copyright: ©Laurie Zawertailo, Tara Mansoursadeghi-Gilan, Helena Zhang, Sarwar Hussain, Bernard Le Foll, Peter Selby. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 18.10.2018.